Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | EBP | Q15125 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767279 | 0.79 | POLB (0.53) | MAPTNPSR1HTR1A | |
| SCHEMBL27638464 | 0.77 | MAPT (0.41) | SIGMAR1MAPTNPSR1HTR6 | |
| SCHEMBL2767412 | 0.77 | MAPT (0.63) | SIGMAR1MAPTNPSR1HTR1ADRD2 | |
| SCHEMBL2765513 | 0.77 | SIGMAR1 (0.65) | SIGMAR1MAPTNPSR1HTR1ADRD2 | |
| SCHEMBL2768860 | 0.76 | ADRA1D (0.61) | SIGMAR1MAPTNPSR1HTR1ADRD2 | |
| SCHEMBL27638449 | 0.76 | MAPT (0.42) | MAPTNPSR1HTR1AHTR6 | |
| SCHEMBL16742541 | 0.75 | INSR (0.46) | MAPTNPSR1 | |
| SCHEMBL2767154 | 0.75 | ADRB1 (0.56) | SIGMAR1MAPTHTR1AHTR6 | |
| SCHEMBL2767785 | 0.73 | SIGMAR1 (0.56) | SIGMAR1MAPTNPSR1HTR1ADRD2 | |
| SCHEMBL3137445 | 0.73 | MAPT (0.53) | MAPTDRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627871-B1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7449466-B2 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | SIGMAR1 1062/4885MAPT 4852/4885NPSR1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.